2-(1-(3-(dimethylamino)propyl)-1H-indazol-3-yl)acetamide | 436159-87-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-(1-(3-(dimethylamino)propyl)-1H-indazol-3-yl)acetamide
• 英文别名: 1-[3-(Dimethylamino)propyl]-1H-indazole-3-acetamide；2-[1-[3-(dimethylamino)propyl]indazol-3-yl]acetamide
• CAS: 436159-87-4
• 化学式: C₁₄H₂₀N₄O
• 分子量: 260.339
• InChiKey: FTKIYOHVANBMSE-UHFFFAOYSA-N

物化性质

• 沸点：
  472.4±35.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  64.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1-(3-(dimethylamino)propyl)-1H-indazol-3-yl)acetamide 、 1-(3-benzo[b]thienyl)-indol-3-yl glyoxylic methyl ester 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以40%的产率得到3-(1-benzo[b]thien-3-yl-1H-indol-3-yl)-4-[1-[3-(dimethylamino)propyl]-1H-indazol-3-yl]-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  Novel Indolylindazolylmaleimides as Inhibitors of Protein Kinase C-β:  Synthesis, Biological Activity, and Cardiovascular Safety

  摘要：

  Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-beta with good to excellent selectivity vs other PKC isozymes and GSK-3 beta. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-beta II (IC50 = 20-25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QT(c) in guinea pigs.

  DOI：

  10.1021/jm049478u
• 作为产物：
  描述：

  吲唑-3-乙酸 在 sodium hydride 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 2-(1-(3-(dimethylamino)propyl)-1H-indazol-3-yl)acetamide
  参考文献：
  名称：

  Novel Indolylindazolylmaleimides as Inhibitors of Protein Kinase C-β:  Synthesis, Biological Activity, and Cardiovascular Safety

  摘要：

  Novel indolylindazolylmaleimides were synthesized and examined for kinase inhibition. We identified low-nanomolar inhibitors of PKC-beta with good to excellent selectivity vs other PKC isozymes and GSK-3 beta. In a cell-based functional assay, 8f and 8i effectively blocked IL-8 release induced by PKC-beta II (IC50 = 20-25 nM). In cardiovascular safety assessment, representative lead compounds bound to the hERG channel with high affinity, potently inhibited ion current in a patch-clamp experiment, and caused a dose-dependent increase of QT(c) in guinea pigs.

  DOI：

  10.1021/jm049478u

文献信息

• NOVEL THIENOPYRROLE COMPOUNDS
  申请人：Wishart Neil

  公开号：US20110152243A1

  公开（公告）日：2011-06-23

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了公式（I）的化合物，包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可用于治疗免疫和肿瘤疾病。
• Indazolyl-substituted pyrroline compounds as kinase inhibitors
  申请人：Zhang Han-Cheng

  公开号：US20080096949A1

  公开（公告）日：2008-04-24

  The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.

  本发明涉及新型的取代吲唑基吡咯烷化合物，化学式为(I)：用作激酶或双重激酶抑制剂，制备这种化合物的方法以及用于治疗或改善激酶或双重激酶介导的疾病的方法。
• SUBSTITUTED PYRROLINE KINASE INHIBITORS
  申请人：Zhang Han-Cheng

  公开号：US20090181982A1

  公开（公告）日：2009-07-16

  The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.

  本发明涉及一种新的取代吡咯烷化合物，可用作激酶抑制剂，并用于治疗或改善激酶介导的疾病的方法。
• Substituted pyrroline kinase inhibitors
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP1900738A2

  公开（公告）日：2008-03-19

  The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder, Formula (I), wherein R is selected from the group consisting of Ra, -C1-8alkyl-Ra, -C2-8alkenyl-Ra, -C2-8alkynyl-Ra and cyano; Ra is selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl.

  本发明涉及作为激酶抑制剂的新型取代吡咯啉化合物以及治疗或改善激酶介导的紊乱的方法，式（I）中，R选自由Ra、-C1-8烷基-Ra、-C2-8烯基-Ra、-C2-8炔基-Ra和氰基组成的组；Ra选自由环烷基、杂环烷基、芳基和杂芳基组成的组。
• US7304060B2
  申请人：——

  公开号：US7304060B2

  公开（公告）日：2007-12-04